

CARDIOTHORACIC SURGERY COLLABORATIVE CLINICAL RESEARCH OPPORTUNITIES

“Therapies for advanced heart failure; Opportunities and Gaps; A cardiologist’s perspective on the future: LVAD as a bridge to cell-based therapies”

**Clyde W. Yancy, MD, MSc, FACC, FAHA, MACP
Magerstadt Professor of Medicine
Chief of Cardiology
Northwestern University, Feinberg School of Medicine
&
Associate Medical Director
Bluhm Cardiovascular Institute
Chicago, IL
cyancy@nmff.org**

DISCLOSURES

- **Consultant/speaker/honoraria: none**
- **Editorial Boards: American Heart Journal, American Journal of Cardiology (*associate editor*); Circulation; Circulation-Heart Failure; Circulation- Quality Outcomes; Congestive Heart Failure**
- **Guideline writing committees: ACC/AHA, chronic HF; & hypertrophic cardiomyopathy and ACC/AHA Guideline Taskforce**
- **Federal appointments: FDA: Past Chair, Cardiovascular Device Panel; ad hoc consultant; NIH CICS study section; advisor; AHRQ- adhoc study section chair; NHLBI- consultant; PCORI- committee member**
- **Volunteer Appointments: American Heart Association- President, American Heart Association, 2009-2010**

Destination Therapy Trials Summary






Figure 1. Survival Rates in Two Trials of Left Ventricular Assist Devices (LVADs) as Destination Therapy.


The curves labeled 2009 are those reported by Slaughter and colleagues in this issue of the *Journal*²; those labeled 2001 were reported for the REMATCH trial.¹

A







B






20 mM caffeine







% LV Infarction



A



B



C



Using the prism of a Cardiologist...

- The growth opportunity for LVADs is in destination therapy, bridge to recovery and especially bridge to cell-based therapies
- LVAD application changes the biology of failing myocardium and converts failing into non-failing
- SINGLE MOST IMPORTANT RESEARCH OPPORTUNITY: *creating synergy between response to LVAD and cell-based therapies to maximize recovery*